Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Moderna's MRNA-3927?
MRNA-3927 is a gene therapy commercialized by Moderna, with a leading Phase II program in Propionic Acidemia. According to Globaldata,...
MRNA-3927 by Moderna for Propionic Acidemia: Likelihood of Approval
MRNA-3927 is under clinical development by Moderna and currently in Phase II for Propionic Acidemia. According to GlobalData, Phase II...
Risk adjusted net present value: What is the current valuation of Moderna's MRNA-3927?
MRNA-3927 is a gene therapy commercialized by Moderna, with a leading Phase II program in Propionic Acidemia. According to Globaldata,...